EP-100 Phase 1 Results Revealed by Esperance

Esperance Pharmaceuticals introduced its Phase 1 study of EP-100, a novel specified membrane‐disrupting peptide in superior solid tumors along at the American Society for Clinical Oncology (ASCO) Yearly Gathering in Chicago, Illinois. EP‐100 requires seek and damage cancer cells that in fact over‐express luteinizing hormone releasing hormone (LHRH) sense organs upon their surfaces. LHRH sense organs are over‐expressed in a wide variety of cancers.

The Phase 1 study was created to work out safety and most dose of EP-100, such as a suggested dose for Phase 2 trials. Based upon clinical experience of escalating dosages in 38 affected individuals within the Phase 1 study and on preclinical studies revealing synergy of EP-100 along with different chemotherapeutic elements, Esperance has begun joining of affected individuals within a Phase 2 multi‐center trial for sufferers along with advanced ovarian melanoma randomized to actually EP‐100 in conjunction with paclitaxel versus paclitaxel alone.

"Results coming from the Phase 1 study recommend that LHRH expression is a practicable target for session, understanding that EP-100 has possible being a targeted, well-tolerated therapeutic for tumor therapy in places in which many affected individuals are exhausting of alternatives," said lead investigator Ramesh K. Ramanathan, MD from the Virginia G. Piper Cancer Center/TGen, (Scottsdale, AZ). "I look forward to carrying on with progress with this particular exciting, new drug applicant in a number of later step clinical trials."